The relationship between ProNT BNP levels and erectiledysfunction in patients with chronic congestive heartfailure

Aim: Dysfunction and impairment of many organs occur in chronic congestive heart failure due to ischemia and stasis. Chroniccongestive heart failure is frequently accompanied by erectile dysfunction since the two conditions have many etiologic factors incommon. Our aim in the study was to investigate the potential relationship between ProNT BNP levels, which show the severity ofcardiac failure, and erectile dysfunction in patients with an ejection fraction of 30-40%.Materials and Methods: The study included 72 male patients followed-up for chronic congestive heart failure. for whom erectiledysfunction was investigated. International Erectile Function Index-5 (IIEF-5) questionnaire was questioned to the patients toevaluate erectile function. Results: The mean age, total testosterone and lipids (low and high-density lipoprotein cholesterol triglyceride) levels did notsignificantly differ between the groups (P > 0.05). The mean ProNT BNP levels belonging to all subgroups showed statisticallysignificant differences and correlated with the severity of erectile dysfunction according to the Kruskal-Wallis test (p

PDF

___

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.
2. Chaney E, Shaw A. Pathophysiology of fluid retention in heart failure. Contrib Nephrol 2010;164:46-53.
3. Schwarz ER, Rastogi S, Kapur V, et al. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006;48:1111-9.
4. Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000;86:41-5.
5. Gupta S, Salimpour P, Saenz de Tejada I, et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol 1998;159:1529-36.
6. Zeighami Mohammadi S, Shahparian M, Fahidy F, et al. Sexual dysfunction in males with systolic heart failure and associated factors. ARYA Atheroscler 2012;8:63- 9.
7. Schwarz ER, Kapur V, Bionat S, et al. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int J Impot Res 2008;20:85-91.
8. Emdin M, Passino C, Prontera C, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004;42:627-36.
9. Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006;119:70.23-30.
10. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008;51:2040-4.
11. Frantzen J, Speel TG, Kiemeney LA, et al. Cardiovascular risk among men seeking help for erectile dysfunction. Ann Epidemiol. 2006;16:85-90.
12. Rogowski O, Shnizer S, Wolff R, et al. Increased serum levels of oxidative stress are associated with hospital readmissions due to acute heart failure. Cardiology 2011;118:33-7.
13. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149-55.
14. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
15. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res 1999;11:141-3.
16. Ginsberg TB. Aging and sexuality. Med Clin North Am. 2006;90:1025-36.
17. De Marco T, Wolfel E, Feldman AM, et al. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail 2008;14:9- 18.
18. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999;230:132-42.
19. Morrow DA. Cardiovascular risk prediction in patients with stable and unstable coronary heart disease. Circulation 2010;121:2681-91.
20. Chung I-H, Yoo BS, Ryu HY, et al. The relationship between the early follow-up BNP level and congestive status or prognosis in acute heart failure. Korean Circulation J 2006;36:200-7.
21. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int J Mol Sci 2019;20:1820.